nmCRPC COE

The VISION Trial: Radionuclide Therapy Plus Standard Therapy for Metastatic Castration Resistant Prostate Cancer - Oliver Sartor and Michael Morris

Details
At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019), Oliver Sartor and Michael Morris join Charles to discuss lutetium in advanced prostate cancer and the VISION trial. Dr. Michael Morris serves on the scientific oversight committee of the trial, and Dr. Sartor is one of the co-PIs of this clinical trial. The VISION trial has the potential to change clinical practice in the...

Optimal Treatment of Newly Diagnosed Metastatic Prostate Cancer Presentation - Noel Clarke

Details
Noel Clarke presented on the optimization of the treatment of newly diagnosed metastatic prostate cancer at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). Among the topics he covers in this presentation include the STAMPEDE biomedical imaging group (BIG) and STAMPEDE biomedical research group (BRG) which have incorporated 5,000 CT and bone scans with a target of more than 10,000,...

The Definition and Overview of Treatment Options in nmCRPC Presentation - Howard Scher

Details
Howard Scher presents an overview of treatment options for non-metastatic castration-resistant prostate cancer, (nmCRPC), those patients who never had detectable metastases on “conventional/standard” imaging, which includes a radionuclide bone scan and CT abdomen/pelvis +/- and MRI. These patients are generally asymptomatic from cancer itself with some symptoms from prior therapies. Importantly, t...

The Treatment of Non-Metastatic Castration-Resistant Prostate Cancer: "Pros" Presentation - Maha Hussain

Details
Maha Hussain presents during the Management of Castration-Resistant Prostate Cancer (CRPC) debate at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Dr. Hussain focuses on the "pros" of treating men with non-metastatic CRPC while revisiting the transformation of the field back to 2011 where stood an area of unmet need. The past 18 months have seen the reporting and FDA approval of...

The "Cons" of Treating nmCRPC - Important Considerations to Take into Account Presentation - Celestia Higano

Details
Celestia (Tia) Higano followed Maha Hussain's presentation on the "pros" of the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) with the opposing side of the debate at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Dr. Higano focuses on the "cons" of treating men with nmCRPC and highlights an extensively covered topic at the meeting, the emergence and upd...

Preview of the Advanced Prostate Cancer Consensus Conference 2019 (APCCC) - Silke Gillessen and Aurelius Omlin

Details
Silke Gillessen, MD and Aurelius Omlin, MD discuss the inception of the biennial Advanced Prostate Cancer Consensus Conference (APCCC) which will be held in Basel this August. The intent of the meeting is to drive international consensus on key areas of prostate cancer practice where there are no clear guidelines or level 1 evidence. 75% of the panelists must agree on each topic to reach a consens...

Abiraterone Acetate for nmCRPC, The Forgotten Dance Partner? - Zach Klaassen and Chris Wallis

Details
Zach Klaassen and Chris Wallis discuss a jointly published paper that was published in Jama Oncology, November, titled, “Abiraterone Acetate for Nonmetastatic Castration-Resistant Prostate Cancer, The Forgotten Dance Partner?” They reference recent trials in this space and discuss cost and other variables to consider when making a therapeutic decision. Biographies: Zachary Klaassen, MD, MSc, Urolo...

Comparison Between Surgery and Radiotherapy in the Treatment of Non-Metastatic Prostate Cancer- Christopher Wallis

Details
(Length of Presentation: 8 minutes) Christopher Wallis presents observational data from a large, population-based matched cohort demonstrating an association between treatment with radiotherapy vs radical prostatectomy and non-prostate cancer mortality. This controversial topic in urologic oncology is a usual subject of interest with respect to comparative effectiveness studies. In observational s...

Phase III ARAMIS Trial Darolutamide in Patients with Non-metastatic Castration-resistant Prostate Cancer Meets Primary Endpoint - Tom Keane

Details
(Length of video: 5 min) Tom Keane, MBBCh, FRCSI, FACS provides highlights of the recent press release of ARAMIS, a phase III trial of darolutamide in patients with non-metastatic castrate-resistant prostate cancer. Darolutamide significantly extended metastasis-free survival compared to placebo, meeting its primary endpoint. The safety profile and tolerability of darolutamide observed in the ARAM...

nmCRPC Patient Population - Discussion with Charles Ryan and Alicia Morgans

Details
Charles Ryan and Alicia Morgans discuss the M0 patient population and what is the meaning of the term "nonmetastatic" prostate cancer. They highlight the relevance of meaningful dialogue that should be had with patients to assure the right treatment choice is made. Biographies: Charles J. Ryan, MD Alicia Morgans, MD, MPH
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe